BioVie Announces Pipeline Update and Near-Term Clinical Priorities
CARSON CITY, Nev., March 11, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that its recently completed funding round provides opportunity to further the Company’s clinical priorities in Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and ascites/liver disease. The Company continues to explore longevity and aging in conjunction with external collaborators.
- The Company continues to explore longevity and aging in conjunction with external collaborators.
- The trial targets enrolling 100-150 patients in a 6-month trial with the Part 3 (motor) score on the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the primary endpoint.
- Only one Phase 3 trial is potentially needed as BIV201 has already received Orphan and Fast Track designations.
- BIV201 remains our most de-risked program, but it unfortunately is a program that will take two years to complete.